- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03279523
F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected
F 18 T807 Tau PET Imaging of Older (>= 40 Years Old) HIV Infected (HIV+) and HIV Uninfected (HIV-) Individuals (IND 123119, Protocol G)
Studieoversigt
Detaljeret beskrivelse
This protocol will demonstrate the presence of tau fibrils in older HIV+ patients with HIV associated neurocognitive disorders (HAND) compared to cognitively normal HIV+ individuals and HIV- controls.
It will also demonstrate that the phenoconversion from cognitively normal (CN) status to HAND will be closely correlated with neocortical F 18 T807 uptake. In particular, HIV+ patients with MND will have greater tau cortical deposition compared to ANI individuals.
The investigtors hypothesize that in vivo tau imaging will ultimately:
- Demonstrate the presence of tau fibrils in older HIV+ patients with HIV associated neurocognitive disorders (HAND) compared to cognitively normal HIV+ individuals and HIV- controls.
- Demonstrate that the phenoconversion from cognitively normal (CN) status to HAND will be closely correlated with neocortical F 18 T807 uptake. In particular, HIV+ patients with MND will have greater tau cortical deposition compared to ANI individuals.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Male or female participants, ≥ 40 years of age.
- Testing for HIV status. If positive will be included in the HIV+ group and if negative will be included in the HIV- group.
- Females without documented history of menopause or hysterectomy will undergo a urine pregnancy test 24 hours prior to F 18 T807 drug administration.
Exclusion Criteria:
- Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures).
- Is deemed likely unable to perform the imaging procedures for any reason.
- Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval.
- Has hypersensitivity to F 18 T807 or any of its excipients.
- Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate.
- Severe claustrophobia.
- Currently pregnant or breast-feeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
F 18 T807
Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
|
Deltagerne vil modtage en enkelt intravenøs bolusinjektion på ca. 6,5-10mCi (240-370MBq) F 18 T807.
For dem, der ikke kan tolerere hele undersøgelsen, vil deltagerne modtage en enkelt intravenøs bolusinjektion på ca. 6,5-10mCi (240-370MBq) af F 18 T807.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 40 years old) HIV+ participants and 30 HIV- controls.
Tidsramme: 5 years
|
5 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.
Tidsramme: 5 years
|
5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Tammie Benzinger, MD, PhD, Washington University School of Medicine
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IND 123119 Protocol G
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med F 18 T807
-
Avid RadiopharmaceuticalsAfsluttetAlzheimers sygdom | ADForenede Stater
-
Avid RadiopharmaceuticalsAfsluttet
-
Tammie L. S. Benzinger, MD, PhDTrukket tilbage
-
Avid RadiopharmaceuticalsAfsluttet
-
Tammie L. S. Benzinger, MD, PhDRekruttering
-
Washington University School of MedicineTilmelding efter invitationF 18 T807 Tau PET-billeddannelse i Dominantly Inherited Alzheimer's Network (DIAN-projekt) (AV ADAD)Alzheimers sygdomForenede Stater
-
Tammie L. S. Benzinger, MD, PhDAfsluttetAlzheimers sygdom | Progressive Posterior Cortical Dysfunction (PPCD)Forenede Stater
-
Avid RadiopharmaceuticalsTrukket tilbage
-
Tammie L. S. Benzinger, MD, PhDTrukket tilbageAlzheimers sygdomForenede Stater
-
Tammie L. S. Benzinger, MD, PhDAfsluttetAmyotrofisk lateral sklerose (ALS)Forenede Stater